{"schema_version":"secwatch.filing_event.v1","accession":"0001778922-26-000052","form_type":"8-K","ticker":"SGP","cik":"0001778922","company_name":"SpyGlass Pharma, Inc.","filed_at":"2026-10-19T20:10:28+00:00","discovered_at":"2026-10-19T20:11:00.263349+00:00","generated_at":"2026-10-19T20:11:04.157360+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SpyGlass reports 4-year BIM-IOL data: 37% IOP cut, 86% off drops, no product-related AEs","bullets":["Interim 4-year data in 21 evaluable patients: mean IOP fell 37% to 15.9 mmHg from 25.1 mmHg post-washout across 75/150/300 mcg dose groups.","86% (18 of 21) remained off all topical IOP-lowering drops; 90% maintained ≥20/25 best corrected distance visual acuity.","No product-related adverse events reported; FIH trial enrolled 23 patients, with 21 evaluable at 48 months (one moved abroad, one discontinued after cancer diagnosis).","BIM-IOL System is designed to deliver bimatoprost for up to 7 years in the FIH trial; Phase 3 version targets 3 years, with a 505(b)(2) NDA planned.","CEO Patrick Mooney cites approximately 1 million U.S. cataract procedures annually in glaucoma patients as the unmet need being targeted."],"urls":{"canonical":"https://secwatch.observer/filing/0001778922-26-000052","json":"https://secwatch.observer/filing/0001778922-26-000052.json","markdown":"https://secwatch.observer/filing/0001778922-26-000052.md","text":"https://secwatch.observer/filing/0001778922-26-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/0001778922-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T20:11:04.157360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}